Physician profile
Henry Calas
NPI 1871507269
$20,340.06
in general payments reported to CMS, 2019-2025
57 companies · $3,798 in 2025
The $3,798 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,413 · 2020: $2,752 · 2021: $2,881 · 2022: $2,775 · 2023: $2,745 · 2024: $2,977 · 2025: $3,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,440 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,440.23 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,894.84 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,513.64 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $1,388.19 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $1,184.16 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,165.34 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $1,161.64 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,095.49 | 2023-2025 | Rexulti, Nuedexta |
| Emd Serono, INC. | $932.86 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $781.76 | 2019-2022 | |
| Neurelis, INC. | $706.75 | 2020-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $636.06 | 2019-2025 | |
| Biogen, INC. | $616.99 | 2019-2023 | Vumerity |
| Supernus Pharmaceuticals, INC. | $546.50 | 2019-2022 | |
| Sk Life Science, INC. | $492.24 | 2020-2023 | |
| Avanir Pharmaceuticals, INC. | $475.94 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Calas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.